UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Agilent Technologies, Inc. $A

Key Points

• UBS Asset Management reduced its Agilent Technologies stake by 3.8% in the second quarter, selling 101,678 shares and retaining 2.54 million shares worth approximately $338 million.
• Analyst sentiment remains positive, with Agilent carrying a “Moderate Buy” consensus rating and an average price target of $170.33; several firms recently raised their targets to between $175 and $185.
• Agilent exceeded quarterly expectations, reporting $1.62 in adjusted EPS versus the $1.49 consensus and $1.88 billion in revenue, up 8.1% year over year. The company issued fiscal 2026 EPS guidance of $6.18–$6.21.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 3.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,544,780 shares of the medical research company's stock after selling 101,678 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.90% of Agilent Technologies worth $338,023,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. State Street Corp raised its stake in Agilent Technologies by 1.9% in the fourth quarter. State Street Corp now owns 12,681,792 shares of the medical research company's stock worth $1,725,611,000 after buying an additional 241,029 shares in the last quarter. Wellington Management Group LLP boosted its position in Agilent Technologies by 2.7% during the 2nd quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company's stock valued at $990,206,000 after acquiring an additional 198,253 shares in the last quarter. Geode Capital Management LLC boosted its position in Agilent Technologies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 7,425,861 shares of the medical research company's stock valued at $1,006,519,000 after acquiring an additional 25,139 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Agilent Technologies by 17.1% in the 2nd quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company's stock valued at $930,957,000 after acquiring an additional 1,024,516 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Agilent Technologies by 87.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company's stock worth $695,227,000 after acquiring an additional 2,440,360 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on A shares. Wall Street Zen upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Sunday, August 2nd. The Goldman Sachs Group boosted their target price on shares of Agilent Technologies from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 27th. Stifel Nicolaus increased their price target on shares of Agilent Technologies from $170.00 to $180.00 and gave the company a "buy" rating in a research report on Thursday, August 27th. Royal Bank Of Canada raised their price target on shares of Agilent Technologies from $155.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, August 27th. Finally, Piper Sandler initiated coverage on shares of Agilent Technologies in a research report on Thursday, June 11th. They issued a "neutral" rating and a $150.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $170.33.

Agilent Technologies Trading Down 0.0%

Shares of NYSE:A opened at $153.79 on Tuesday. The business's 50-day moving average is $140.85 and its 200 day moving average is $127.21. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.05 and a quick ratio of 1.56. Agilent Technologies, Inc. has a 1 year low of $108.35 and a 1 year high of $163.75. The firm has a market capitalization of $43.43 billion, a P/E ratio of 30.27, a P/E/G ratio of 2.34 and a beta of 1.25.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The business had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter last year, the company earned $1.37 earnings per share. The company's quarterly revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 6.2 earnings per share for the current fiscal year.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.